Dashboard
Manage Tickers

BBIO BridgeBio Pharma, Inc.

Nasdaq bridgebio.com


$ 62.41 $ 0.00 (0 %)    

Monday, 03-Nov-2025 05:42:58 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.24 $ 0.00 (0 %)
DIA $ 475.94 $ 0.00 (0 %)
SPY $ 684.60 $ 0.00 (0 %)
TLT $ 90.03 $ 0.00 (0 %)
GLD $ 368.40 $ 0.00 (0 %)
$ 62.64
$ 63.88
$ 62.37 x 10
$ 66.01 x 1
-- - --
$ 21.72 - $ 69.48
2,470,591
na
12.07B
$ 1.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-29-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 04-29-2025 03-31-2025 10-Q
4 02-20-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-25-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-11-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-03-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-bridgebio-pharma-maintains-90-price-target
HC Wainwright & Co. Reiterates Buy on Brid...
11/03/2025 11:48:14

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $90 pr...

goldman-sachs-maintains-buy-on-bridgebio-pharma-raises-price-target-to-100
Goldman Sachs Maintains Buy on BridgeBio P...
10/31/2025 17:41:57

Goldman Sachs analyst Paul Choi maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $55 to ...

td-cowen-maintains-buy-on-bridgebio-pharma-raises-price-target-to-95
TD Cowen Maintains Buy on BridgeBio Pharma...
10/30/2025 20:10:22

TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $60 to...

raymond-james-reiterates-outperform-on-bridgebio-pharma-raises-price-target-to-71
Raymond James Reiterates Outperform on Bri...
10/30/2025 14:34:32

Raymond James analyst Martin Auster reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target ...

cantor-fitzgerald-maintains-overweight-on-bridgebio-pharma-raises-price-target-to-110
Cantor Fitzgerald Maintains Overweight on ...
10/30/2025 13:45:37

Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price targ...

piper-sandler-maintains-overweight-on-bridgebio-pharma-raises-price-target-to-98
Piper Sandler Maintains Overweight on Brid...
10/30/2025 13:34:40

Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from...

truist-securities-reiterates-buy-on-bridgebio-pharma-raises-price-target-to-80
Truist Securities Reiterates Buy on Bridge...
10/30/2025 12:32:21

Truist Securities analyst Danielle Brill reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target fr...

bridgebio-pharma-q3-eps-095-misses-089-estimate-sales-120700m-beat-106386m-estimate
BridgeBio Pharma Q3 EPS $(0.95) Misses $(0...
10/29/2025 20:02:13

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(...

bridgebios-investigation-drug-outperforms-standard-therapy-in-rare-calcium-disorder
BridgeBio's Investigation Drug Outperforms...
10/29/2025 18:22:58

BridgeBio's Encaleret met its Phase 3 endpoint in ADH1, with 76% achieving calcium targets, supporting plans for FDA and EM...

hc-wainwright--co-maintains-buy-on-bridgebio-pharma-raises-price-target-to-90
HC Wainwright & Co. Maintains Buy on Bridg...
10/29/2025 17:44:31

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price ...

earnings-scheduled-for-october-29-2025
Earnings Scheduled For October 29, 2025
10/29/2025 11:11:56

bridgebio-pharma-announced-topline-results-from-calibrate-phase-3-study-of-encaleret-in-autosomal-dominant-hypocalcemia-type-1-meeting-all-pre-specified-primary-and-key-secondary-efficacy-endpoints
Bridgebio Pharma Announced Topline Results...
10/29/2025 11:11:30

The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints.The ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/28/2025 21:13:44

bridgebio-pharma-to-release-topline-phase-3-results-from-its-calibrate-trial-for-autosomal-dominant-hypocalcemia-type-1-adh1-on-october-28-2025-before-market-open
BridgeBio Pharma To Release Topline Phase ...
10/28/2025 20:04:29

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company fo...

earnings-outlook-for-bridgebio-pharma
Earnings Outlook For BridgeBio Pharma
10/28/2025 16:01:47

hc-wainwright--co-maintains-buy-on-bridgebio-pharma-raises-price-target-to-80
HC Wainwright & Co. Maintains Buy on Bridg...
10/28/2025 11:50:17

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price ...

janus-henderson-avidity-biosciences-bridgebio-pharma-and-other-big-stocks-moving-higher-on-monday
Janus Henderson, Avidity Biosciences, Brid...
10/27/2025 14:21:30

bridgebio-announces-all-primary-and-secondary-interim-analysis-endpoints-in-fortify-phase-3-study-were-successfully-achieved
BridgeBio Announces All Primary And Second...
10/27/2025 11:02:49

bridgebio-pharma-to-host-webinar-on-limb-girdle-muscular-dystrophy-type-2ir9-lgmd2ir9-fortify-phase-3-interim-analysis-topline-results-on-october-27-2025-at-800am-et
BridgeBio Pharma To Host Webinar On Limb-g...
10/24/2025 20:03:58

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company fo...

raymond-james-maintains-outperform-on-bridgebio-pharma-raises-price-target-to-59
Raymond James Maintains Outperform on Brid...
10/21/2025 17:52:19

Raymond James analyst Martin Auster maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target f...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION